Skip to main content
. 2020 Jul 29;11(9):2639–2649. doi: 10.1111/1759-7714.13596

Table 5.

SA‐4: NSCLC mutant EGFR group

IGRT (n = 30) non‐IGRT (n = 30) Standardized difference (rounded)*
Number or mean (sd) § (%) § Number or mean (sd) § (%) §
Age <65 12 (40) 16 (53) 0.27
≥65 18 (60) 14 (47)
Gender Female 19 (63) 20 (67) 0.07
Male 11 (37) 10 (33)
Residency Non‐north 21 (70) 17 (57) 0.28
North 9 (30) 13 (43)
Social economic status No more than minimum wage 8 (27) 10 (33) 0.15
Higher 22 (73) 20 (67)
Comorbidity Without 20 (67) 17 (57) 0.21
With 10 (33) 13 (43)
Clinical stage 3A 12 (40) 9 (30) 0.21
3B 18 (60) 21 (70)
Tumor location Lower 5 (17) 3 (10) 0.20
Upper/middle 25 (83) 27 (90)
Peri‐CCRT Systemic therapy Without 8 (27) 11 (37) 0.22
With 22 (73) 19 (63)
RT break ≤1 week 26 (87) 25 (83) 0.09
>1 week 4 (13) 5 (17)
RT dose 62.52 (5.62) 62.15 (4.69) 0.07
BMI 24.30 (3.87) 24.19 (3.37) 0.03
Drinking No 26 (87) 24 (80) 0.18
Yes 4 (13) 6 (20)
Betel nut chewing No 0.15
Yes
Smoking No 23 (77) 21 (70) 0.15
Yes 7 (23) 9 (30)
Use of PET No 14 (47) 13 (43) 0.07
Yes 16 (53) 17 (57)
Tumor size (mm) 49.13 (18.48) 47.17 (22.27) 0.10

All patients were performance status score 0–1 and treated by intensity‐modulated radiotherapy. BMI, body mass index; CCRT, concurrent chemoradiotherapy; IGRT, image‐guided radiotherapy; IMRT, intensity‐modulated radiotherapy; PET, positron emission tomography; PSW, propensity‐score weighting; RT, radiotherapy; SCLC, small cell lung cancer; sd, standard deviation.

Modified Carlson comorbidity score ≥ 1.

The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤2).

§

Rounded.